The Clinical Research For Prevention Of Stroke-associated Pneumonia With Nasal Feeding Of Tobramycin Joint Mosapride

Objective:To observe the preventive effect of stroke-associated pneumonia with nasalfeeding of Tobramycin joint Mosapride，and investigate the effect of digestive tractdepuration in preventing stroke-associated pneumonia.Methods:We investigated138cases of acute stroke with consciousness disorders orswallowing disorders,which were divided into intervention group and control group with69cases.Both groups were given nasal feeding and nutrition-based treatment,and theintervention group were given Mosapride5mg each time and Tobramycin injection80mgeach time by nasogastric tube, every8hours;pharyngeal coated with tobramycin ointment1g each time, every8hours.And the control group with same amount of saline.Observe theoccurrence of stroke-associated pneumonia in both groups,etc.Results:(1)The stomach pharyngeal cavity bacteria reverse engraftment rate ofintervention group was22.6%（14/62），the control group was45.5%（30/66）, thedifference was statistically significant(P<0.01);(2)The incidence of SAP in3day,one weekand two week was14.5%(9/62),17.7%(11/62),21%(13/62)in the intervention group,andwas31.8%(21/66),43.9%(29/66),50%(33/66)in the control group,the difference wasstatistically significant(P<0.05);(3)The average days of treatment SAP in the interventiongroup was7.26±3.17,the control group was13.32±3.79,the difference was statisticallysignificant(P<0.05);(4)SAP attribution of mortality of intervention group was3.2%(2/62),the control group was13.6%(9/66),the difference was statistically significant(P<0.05).Conclusion: Nasal feeding of Tobramycin joint Mosapride helpd to reduce theincidence of SAP significantly,reduce the SAP attribution of mortality,and significantly reduce the length of antibiotic treatment in patients with SAP.